Etid klinik pou Sipwa nan Austin, TX
18 etid pou Sipwa ap chèche patisipan nan sit nan ak bò kote Austin (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
Ap rekriteFaz 2
- Elligo Clinical Research Center /ID# 282166, Austin
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
Ap rekriteFaz 3
- Texas Diabetes & Endocrinology, Austin
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Ap rekriteFaz 3
- IMA Clinical Research Austin, Austin
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Ap rekriteFaz 3
- Dell Children's Medical Center - PIN, Austin
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Ap rekriteFaz 3
- Austin Heart, Austin
- Velocity Clinical Research - Austin, Austin
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Ap rekriteFaz 3
- FutureSearch Trials of Neurology, Austin
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
Ap rekriteFaz 2
- IMA Clinical Research Austin, Austin
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Ap rekriteFaz 3
- IMA Clinical Research Austin, Austin
Semaglutide for Post-Smoking Cessation Weight Management
Ap rekriteFaz 2Volontè an sante akeyi
- The University of Texas at Austin, Austin
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Ap rekriteFaz 3
- AURORA-1 Clinical Site, Austin
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Ap rekriteFaz 3
- AURORA-2 Clinical Site, Austin
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Ap rekriteFaz 3Volontè an sante akeyi
- ACCOMPLISH-2 Research Site, Austin
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Ap rekriteFaz 2
- IMA Clinical Research Austin, Austin
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
Ap rekriteFaz 3
- Elligo Clinical Research Center, Austin
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
Ap rekriteFaz 3
- Elligo Clinical Research Center, Austin
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Ap rekriteFaz 3
- ACCOMPLISH-1 Research Site, Austin
- ACCOMPLISH-1 Research Site, Austin
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
Ap rekriteFaz 1
- Elligo Clin Res Centre, Austin
A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets
Ap rekriteFaz 1
- Corxel Investigational Site, Austin
Etid Sipwa nan lòt vil
- San Antonio, TX34 etid
- Houston, TX33 etid
- Chicago, IL28 etid
- Orlando, FL27 etid
- Las Vegas, NV23 etid
- Miami, FL23 etid
- Atlanta, GA20 etid
- Dallas, TX20 etid
- Washington, DC19 etid
- New York City, NY19 etid
- Jacksonville, FL19 etid
- Havelock, NC17 etid
Lòt etid nan Austin
- Kansè Poumon ki pa ti selil30 etid
- Kansè (tout kalite)20 etid
- Obèsite20 etid
- Kansè kolorektal19 etid
- Kansè Metastatik19 etid
- Kansè nan tete18 etid
- Ensifizyans kadyak18 etid
- Kansè ovè17 etid
- Kansè Endomèt15 etid
- Kansè pwostat15 etid
- Depresyon14 etid
- Maladi fwa steatotik13 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.